Dingdang Health Technology Group Ltd. disclosed that it repurchased 1.44 million ordinary shares on 8 September 2026 through on-market transactions on the Stock Exchange of Hong Kong.
The buyback was executed within a price range of HKD 0.81 to HKD 0.87 per share, with a volume-weighted average cost of HKD 0.84 and an aggregate consideration of HKD 1.21 million. All repurchased shares have been retained as treasury shares.
Following the transaction, Dingdang Health’s issued share capital (excluding treasury shares) fell by 0.12% to 1.24 billion shares, while treasury shares increased from 2.08 million to 3.52 million. The total number of issued shares remained unchanged at 1.24 billion.
The purchase was made under the repurchase mandate approved on 23 June 2026, which authorises the company to buy back up to 124.32 million shares. To date, Dingdang Health has repurchased 6.38 million shares under this mandate, representing 0.51% of the shares outstanding as at the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 8 October 2026.
The board confirmed that the repurchase complied with all relevant regulations and that all requisite approvals and filings have been duly completed.
Comments